Elanco Animal Health (NYSE:ELAN) Price Target Lowered to $17.00 at UBS Group

Elanco Animal Health (NYSE:ELAN) had its price objective lowered by research analysts at UBS Group from $18.00 to $17.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price objective would indicate a potential upside of 50.78% from the stock’s current price.

ELAN has been the topic of a number of other reports. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday. Stifel Nicolaus reduced their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Finally, Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $15.57.

Elanco Animal Health Stock Performance

Elanco Animal Health stock traded up $0.58 on Wednesday, hitting $11.28. The company’s stock had a trading volume of 2,877,146 shares, compared to its average volume of 4,853,261. The company has a fifty day moving average price of $11.75 and a 200-day moving average price of $13.07. The firm has a market cap of $5.57 billion, a P/E ratio of 28.21, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a one year low of $10.20 and a one year high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company posted $0.08 EPS. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. On average, equities analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently modified their holdings of the business. Blue Trust Inc. boosted its stake in Elanco Animal Health by 2,129.2% in the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after purchasing an additional 3,790 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Elanco Animal Health by 70.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 19,515 shares of the company’s stock valued at $287,000 after purchasing an additional 8,077 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after acquiring an additional 2,044 shares during the period. Private Management Group Inc. raised its stake in shares of Elanco Animal Health by 62.6% during the 3rd quarter. Private Management Group Inc. now owns 1,442,334 shares of the company’s stock worth $21,188,000 after buying an additional 555,131 shares during the period. Finally, Harbor Capital Advisors Inc. raised its position in Elanco Animal Health by 101.1% during the third quarter. Harbor Capital Advisors Inc. now owns 874,895 shares of the company’s stock worth $12,852,000 after acquiring an additional 439,757 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.